Vedolizumab
Treatment for Ulcerative Colitis
Typical Dosage: 300 mg IV at weeks 0, 2, 6, then every 8 weeks
Effectiveness
75%
Safety Score
65%
Clinical Trials
110
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
300 mg IV at weeks 0, 2, 6, then every 8 weeks
Time to Effect
6-10 weeks
Treatment Duration
Long-term
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40,000
Monitoring:$2,000
Side Effect Mgmt:$1,000
Total Annual:$43,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$264,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$71,666.67
Cost per Remission
$156,363.64
Comparison vs TNF-alpha inhibitors
Cost Difference
+$15,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Active Clinical Trials
4 active trials recruiting for Vedolizumab in Ulcerative Colitis
Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis
NCT05481619RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Zhengzhou, China
Started: Jan 1, 2021
Vedolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab
NCT06614387NOT YET RECRUITINGPHASE3
60 participants
INTERVENTIONAL
Started: Oct 1, 2024
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT06095128RECRUITINGPHASE4
65 participants
INTERVENTIONAL
Dothan, United States +49 more
Started: Jun 12, 2024
Determination of the Optimal Treatment Target in Ulcerative Colitis
NCT04259138ACTIVE NOT RECRUITINGPHASE4
672 participants
INTERVENTIONAL
Ypsilanti, United States +57 more
Started: Feb 18, 2020
Completed Clinical Trials
11 completed trials for Vedolizumab in Ulcerative Colitis
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
NCT04779307COMPLETEDPHASE3
121 participants
INTERVENTIONAL
Phoenix, United States +64 more
Started: Oct 19, 2021
Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
NCT02039505COMPLETEDPHASE3
292 participants
INTERVENTIONAL
Kasugai-shi, Japan +58 more
Started: Feb 4, 2014
Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]
NCT03824561COMPLETED
1.11K participants
OBSERVATIONAL
Tokyo, Japan
Started: Feb 1, 2019
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
NCT00783718COMPLETEDPHASE3
895 participants
INTERVENTIONAL
Birmingham, United States +104 more
Started: Jan 1, 2009
The Associations of Microribonucleic Acid Gene Polymorphisms With the Risk of Ulcerative Colitis
NCT06873711COMPLETED
926 participants
OBSERVATIONAL
Wenzhou, China
Started: Jan 1, 2020
Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
NCT03029143COMPLETEDPHASE4
278 participants
INTERVENTIONAL
Tucson, United States +48 more
Started: Mar 29, 2017
An Analysis of the Relationship Between the Genetic Polymorphisms of Plasminogen Activator Inhibitor-1 and Ulcerative Colitis in Chinese Patients
NCT06961435COMPLETED
900 participants
OBSERVATIONAL
Wenzhou, China
Started: Jan 1, 2019
Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis
NCT01177228COMPLETEDPHASE2
47 participants
INTERVENTIONAL
Started: May 1, 2007
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
NCT03558152COMPLETEDPHASE2
195 participants
INTERVENTIONAL
Greenville, United States +71 more
Started: Oct 26, 2018
Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa
NCT06626165COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Komagane, Japan
Started: Jul 20, 2024
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
NCT02497469COMPLETEDPHASE3
771 participants
INTERVENTIONAL
Mobile, United States +329 more
Started: Jun 29, 2015
Showing 20 of 113 total trials